The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
former turing ceo reflects on crisis after shkreli's arrest
Ron Tilles, who stepped in as interim CEO of Turing Pharmaceuticals after Martin Shkreli's arrest, faced immense challenges managing the fallout from the company's notorious 5,000% price hike of Daraprim. Despite his limited knowledge of the pharmaceutical industry, Tilles worked to stabilize the company amid bankruptcy threats and public outrage, ultimately leading to its rebranding as Vyera Pharmaceuticals. Now a board member at Pyros Pharmaceuticals, Tilles emphasizes the importance of fair pricing in the industry, reflecting on the lessons learned from Turing's tumultuous past.